Independent consulting group, NDA, has announced its findings from its fifth annual comparison of drug approvals in Europe and the US in preparation for this year’s DIA Europe in Basel, Switzerland.
US versus EU
This year’s report has highlighted the continued differences between the two regions and the need for a global approach to drug development to ensure success across both continents.